ARS Pharmaceuticals Inc
SPRY
Get informed when a big investor buys or sells
+ FollowMarket Cap$420.05M
Close$
$-5.75
241.2% downside
Current Fair Value
241.2% downsideOvervalued by 241.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $420.05 Million |
|---|---|
| Enterprise Value | $411.89 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.74 |
| Beta | 0.88 |
| Outstanding Shares | 99,312,526 |
Return
| Return on Equity | -1721.80% |
|---|---|
| Return on Assets | -86.35% |
| Return on Invested Capital | -113.57% |
Valuation & Multiples
| P/E Ratio | -1.94 |
|---|---|
| PEG | -4.99 |
| Price to Sales | 4.07 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.52 |
| Enterprise Value to EBIT | -1.92 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$31.32 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$41.99 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 24.39% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.07%▼ 91.74% |
|---|---|
| Total Invested | $304,605▼ 99.96% |
| Investors Holding | 5▼ 212.00% |
ESG Score
No data
About ARS Pharmaceuticals Inc
54 employeesSilverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administe...